{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:27:45Z","timestamp":1792801665249,"version":"4.5.0"},"reference-count":30,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["CRG\/2018\/000458"],"award-info":[{"award-number":["CRG\/2018\/000458"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["52\/22\/2020-BIO\/BMS"],"award-info":[{"award-number":["52\/22\/2020-BIO\/BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PPL"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>\u03b1-Synuclein, a natively disordered protein, is a key component of Lewy\nbodies, the ubiquitinated protein aggregates which are the pathological hallmark of Parkinson\u2019s disease\n(PD). Meclofenoxate (centrophenoxine) is a nootropic drug which has shown beneficial therapeutic\neffects in various neuronal diseases. Administration of meclofenoxate enhanced levels of dopamine\nand improved motor function in animal models of Parkinson\u2019s disease (PD). Evidence suggested that\ndopamine interacts with and modulates \u03b1-synuclein aggregation.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The aim of this work was to investigate whether the observed positive effect of addition of\nmeclofenoxate, a nootropic agent, on dopamine level, could be correlated with its effect on aggregation\nof \u03b1-synuclein.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Purification of recombinant human \u03b1-synuclein was performed by anion exchange\nchromatography. The purified protein was incubated in the absence and presence of meclofenoxate and\nwas analyzed for aggregation by Thioflavin T fluorescence spectroscopy. Conformational changes in\n\u03b1-synuclein were monitored by fluorescence spectroscopy and fluorescence quenching studies using a\nneutral quencher. Secondary structure analysis of \u03b1-synuclein was monitored by circular dichroism\nspectroscopy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Recombinant human \u03b1-synuclein was expressed and purified by anion-exchange\nchromatography. Incubation of \u03b1-synuclein with meclofenoxate led to lowering aggregation in a\nconcentration-dependent manner. Reduction in formation of oligomers was seen which suggested the\nformation of an off-pathway species which did not give rise to an aggregation-competent entity.\nFluorescence quenching studies revealed that the additive distorted the native conformation of \u03b1-\nsynuclein, leading to the formation of lower amounts of aggregation-prone species.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>In the presence of higher concentrations of meclofenoxate, \u03b1-synuclein undergoes a\nchange in its conformation. This change is not dependent on the concentration of the additive. This\nnon-native conformer promotes the formation of a species which does not undergo further aggregation.\nOur study provides a mechanistic explanation of the earlier observation that meclofenoxate has a\nbeneficial effect on progression of PD in animal models.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929866530666230307113055","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T07:39:14Z","timestamp":1678174754000},"page":"361-366","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Meclofenoxate Inhibits Aggregation of Alpha-synuclein in vitro"],"prefix":"10.2174","volume":"30","author":[{"given":"Adhuna","family":"Parui","sequence":"first","affiliation":[{"name":"Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Sector 67, S.A.S. Nagar,\nPunjab, 160062, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumojit","family":"Biswas","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Sector 67, S.A.S. Nagar,\nPunjab, 160062, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1120-444X","authenticated-orcid":true,"given":"Ipsita","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Sector 67, S.A.S. Nagar,\nPunjab, 160062, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fneur.2018.00295","volume":"9","author":"Ghiglieri V.","year":"2018","unstructured":"Ghiglieri V.; Calabrese V.; Calabresi P.; Alpha-synuclein: From early synaptic dysfunction to neurodegeneration. Front Neurol 2018,9,295","journal-title":"Front Neurol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1093\/brain\/awab242","volume":"144","author":"Tozzi A.","year":"2021","unstructured":"Tozzi A.; Sciaccaluga M.; Loffredo V.; Megaro A.; Ledonne A.; Cardinale A.; Federici M.; Bellingacci L.; Paciotti S.; Ferrari E.; La Rocca A.; Martini A.; Mercuri N.B.; Gardoni F.; Picconi B.; Ghiglieri V.; De Leonibus E.; Calabresi P.; Dopamine-dependent early synaptic and motor dysfunctions induced by \u03b1-synuclein in the nigrostriatal circuit. Brain 2021,144(11),3477-3491","journal-title":"Brain"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4236\/ajac.2016.71009","volume":"7","author":"Zhang P.","year":"2016","unstructured":"Zhang P.; Liu T.; Xu X.; Liu S.; Chen D.; Determination of meclofenoxate content in meclofenoxate hydrochloride for injection by DSC and 1H-NMR. Am J Anal Chem 2016,7(1),92-98","journal-title":"Am J Anal Chem"},{"key":"ref=4","volume":"3","author":"Tammenmaa-Aho I.","year":"2018","unstructured":"Tammenmaa-Aho I.; Asher R.; Soares-Weiser K.; Bergman H.; Cholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 2018,3(3)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1749-6632.1994.tb12077.x","volume":"717","author":"Zs-Nagy I.","year":"1994","unstructured":"Zs-Nagy I.; A survey of the available data on a new nootropic drug, BCE-001. Ann N Y Acad Sci 1994,717(1),102-114","journal-title":"Ann N Y Acad Sci"},{"key":"ref=6","first-page":"1590","volume":"25","author":"Liao Y.","year":"2004","unstructured":"Liao Y.; Wang R.; Tang X.C.; Centrophenoxine improves chronic cerebral ischemia induced cognitive deficit and neuronal degeneration in rats. Acta Pharmacol Sin 2004,25(12),1590-1596","journal-title":"Acta Pharmacol Sin"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1016\/j.neuron.2022.07.011","volume":"110","author":"Kramer P.F.","year":"2022","unstructured":"Kramer P.F.; Brill-Weil S.G.; Cummins A.C.; Zhang R.; Camacho-Hernandez G.A.; Newman A.H.; Eldridge M.A.G.; Averbeck B.B.; Khaliq Z.M.; Synaptic-like axo-axonal transmission from striatal cholinergic interneurons onto dopaminergic fibers. Neuron 2022,110(18),2949-2960.e4","journal-title":"Neuron"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.bbr.2009.12.048","volume":"221","author":"Bohnen N.I.","year":"2011","unstructured":"Bohnen N.I.; Albin R.L.; The cholinergic system and Parkinson disease. Behav Brain Res 2011,221(2),564-573","journal-title":"Behav Brain Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/0028-3908(82)90099-5","volume":"21","author":"Wood P.","year":"1982","unstructured":"Wood P.; P\u00e9loquin A.; Increases in choline levels in rat brain elicited by meclofenoxate. Neuropharmacology 1982,21(4),349-354","journal-title":"Neuropharmacology"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0306-3623(90)90598-G","volume":"21","author":"Petkov V.D.","year":"1990","unstructured":"Petkov V.D.; Stancheva S.L.; Tocuschieva L.; Petkov V.V.; Changes in brain biogenic monoamines induced by the nootropic drugs adafenoxate and meclofenoxate and by citicholine (experiments on rats). Gen Pharmacol 1990,21(1),71-75","journal-title":"Gen Pharmacol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.brainres.2008.01.074","volume":"1201","author":"Nehru B.","year":"2008","unstructured":"Nehru B.; Verma R.; Khanna P.; Sharma S.K.; Behavioral alterations in rotenone model of Parkinson\u2019s disease: Attenuation by co-treatment of centrophenoxine. Brain Res 2008,1201,122-127","journal-title":"Brain Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.neuint.2009.04.001","volume":"55","author":"Verma R.","year":"2009","unstructured":"Verma R.; Nehru B.; Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson\u2019s disease. Neurochem Int 2009,55(6),369-375","journal-title":"Neurochem Int"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1007\/s11064-009-9986-8","volume":"34","author":"Leong S.L.","year":"2009","unstructured":"Leong S.L.; Cappai R.; Barnham K.J.; Pham C.L.L.; Modulation of alpha-synuclein aggregation by dopamine: a review. Neurochem Res 2009,34(10),1838-1846","journal-title":"Neurochem Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.tins.2010.09.004","volume":"33","author":"Venda L.L.","year":"2010","unstructured":"Venda L.L.; Cragg S.J.; Buchman V.L.; Wade-Martins R.; \u03b1-Synuclein and dopamine at the crossroads of Parkinson\u2019s disease. Trends Neurosci 2010,33(12),559-568","journal-title":"Trends Neurosci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jchemneu.2016.06.001","volume":"83-84","author":"Butler B.","year":"2017","unstructured":"Butler B.; Sambo D.; Khoshbouei H.; Alpha-synuclein modulates dopamine neurotransmission. J Chem Neuroanat 2017,83-84,41-49","journal-title":"J Chem Neuroanat"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/mds.27607","volume":"34","author":"Mor D.E.","year":"2019","unstructured":"Mor D.E.; Daniels M.J.; Ischiropoulos H.; The usual suspects, dopamine and alpha\u2010synuclein, conspire to cause neurodegene-ration. Mov Disord 2019,34(2),167-179","journal-title":"Mov Disord"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1096\/fj.04-3437fje","volume":"19","author":"Cappai R.","year":"2005","unstructured":"Cappai R.; Leck S.L.; Tew D.J.; Williamson N.A.; Smith D.P.; Galatis D.; Sharpies R.A.; Curtain C.C.; Ali F.E.; Cherny R.A.; Culvenor J.G.; Bottomley S.P.; Masters C.L.; Barnham K.J.; Hill A.F.; Dopamine promotes \u03b1\u2010synuclein aggregation into SDS\u2010resistant soluble oligomers via a distinct folding pathway. FASEB J 2005,19(10),1377-1379","journal-title":"FASEB J"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1111\/j.1742-4658.2011.08093.x","volume":"278","author":"Jethva P.N.","year":"2011","unstructured":"Jethva P.N.; Kardani J.R.; Roy I.; Modulation of \u03b1-synuclein aggregation by dopamine in the presence of MPTP and its metabolite. FEBS J 2011,278(10),1688-1698","journal-title":"FEBS J"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"21212","DOI":"10.1074\/jbc.M412621200","volume":"280","author":"Norris E.H.","year":"2005","unstructured":"Norris E.H.; Giasson B.I.; Hodara R.; Xu S.; Trojanowski J.Q.; Ischiropoulos H.; Lee V.M.Y.; Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conforma-tional alterations. J Biol Chem 2005,280(22),21212-21219","journal-title":"J Biol Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1134\/S1607672919030025","volume":"486","author":"Ninkina N.N.","year":"2019","unstructured":"Ninkina N.N.; Tarasova T.V.; Chaprov K.D.; Goloborshcheva V.V.; Bachurin S.O.; Buchman V.L.; Synuclein deficiency decreases the efficiency of dopamine uptake by synaptic vesicles. Dokl Biochem Biophys 2019,486(1),168-170","journal-title":"Dokl Biochem Biophys"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/nn.4641","volume":"20","author":"Mor D.E.","year":"2017","unstructured":"Mor D.E.; Tsika E.; Mazzulli J.R.; Gould N.S.; Kim H.; Daniels M.J.; Doshi S.; Gupta P.; Grossman J.L.; Tan V.X.; Kalb R.G.; Caldwell K.A.; Caldwell G.A.; Wolfe J.H.; Ischiropoulos H.; Dopamine induces soluble \u03b1-synuclein oligomers and nigrostriatal degeneration. Nat Neurosci 2017,20(11),1560-1568","journal-title":"Nat Neurosci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1021\/acschemneuro.5b00158","volume":"6","author":"Kardani J.","year":"2015","unstructured":"Kardani J.; Roy I.; Understanding caffeine\u2019s role in attenuating the toxicity of \u03b1-synuclein aggregates: implications for risk of Parkinson\u2019s disease. ACS Chem Neurosci 2015,6(9),1613-1625","journal-title":"ACS Chem Neurosci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jmb.2005.10.071","volume":"355","author":"Apetri M.M.","year":"2006","unstructured":"Apetri M.M.; Maiti N.C.; Zagorski M.G.; Carey P.R.; Anderson V.E.; Secondary structure of \u03b1-synuclein oligomers: characteri-zation by raman and atomic force microscopy. J Mol Biol 2006,355(1),63-71","journal-title":"J Mol Biol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1080\/07391102.2020.1856721","volume":"40","author":"Panuganti V.","year":"2022","unstructured":"Panuganti V.; Roy I.; Oligomers, fibrils and aggregates formed by alpha-synuclein: role of solution conditions. J Biomol Struct Dyn 2022,40(10),4389-4398","journal-title":"J Biomol Struct Dyn"},{"key":"ref=25","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-46312-4","author":"Lakowicz J.R.","year":"2006","unstructured":"Lakowicz J.R.;  Principles of fluorescence spectroscopy 2006","journal-title":"Principles of fluorescence spectroscopy"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1146\/annurev.biophys.37.032807.125924","volume":"37","author":"Uversky V.N.","year":"2008","unstructured":"Uversky V.N.; Oldfield C.J.; Dunker A.K.; Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu Rev Biophys 2008,37(1),215-246","journal-title":"Annu Rev Biophys"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fphy.2019.00010","volume":"7","author":"Uversky V.N.","year":"2019","unstructured":"Uversky V.N.; Intrinsically disordered proteins and their \u201cmysterious\u201d (meta) physics. Front Phys 2019,7,10","journal-title":"Front Phys"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1021\/ar050073t","volume":"39","author":"Fink A.L.","year":"2006","unstructured":"Fink A.L.; The aggregation and fibrillation of alpha-synuclein. Acc Chem Res 2006,39(9),628-634","journal-title":"Acc Chem Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1126\/science.aan6160","volume":"358","author":"Fusco G.","year":"2017","unstructured":"Fusco G.; Chen S.W.; Williamson P.T.F.; Cascella R.; Perni M.; Jarvis J.A.; Cecchi C.; Vendruscolo M.; Chiti F.; Cremades N.; Ying L.; Dobson C.M.; De Simone A.; Structural basis of membrane disruption and cellular toxicity by \u03b1-synuclein oligomers. Science 2017,358(6369),1440-1443","journal-title":"Science"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"44284","DOI":"10.1074\/jbc.M105343200","volume":"276","author":"Uversky V.N.","year":"2001","unstructured":"Uversky V.N.; Li J.; Fink A.L.; Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson\u2019s disease and heavy metal exposure. J Biol Chem 2001,276(47),44284-44296","journal-title":"J Biol Chem"}],"container-title":["Protein &amp; Peptide Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929866530666230307113055","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/214435\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929866530666230307113055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T15:38:58Z","timestamp":1691768338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/214435\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929866530666230307113055","relation":{},"ISSN":["0929-8665"],"issn-type":[{"value":"0929-8665","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-10-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}